Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 6/20 | 0.49 |
| ▸ | HTR2C | P28335 | 6/20 | 0.49 |
| ▸ | HTR2B | P41595 | 4/20 | 0.49 |
| ▸ | NOTUM | Q6P988 | 4/20 | 0.42 |
| ▸ | MET | P08581 | 1/20 | 0.39 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | RORC | P51449 | 1/20 | 0.35 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3787628 | 1.00 | HTR2A (0.49) | HTR2AHTR2CHTR2BNOTUMMET | |
| SCHEMBL3801328 | 0.88 | NOTUM (0.51) | HTR2AHTR2CHTR2BNOTUMMET | |
| SCHEMBL3801331 | 0.88 | NOTUM (0.51) | HTR2AHTR2CHTR2BNOTUMMET | |
| SCHEMBL31121198 | 0.87 | HTR2A (0.47) | HTR2AHTR2CHTR2BNOTUMUSP2 | |
| SCHEMBL3283015 | 0.87 | HTR2A (0.47) | HTR2AHTR2CHTR2BNOTUMUSP2 | |
| SCHEMBL3285518 | 0.87 | HTR2A (0.47) | HTR2AHTR2CHTR2BNOTUMUSP2 | |
| SCHEMBL3290318 | 0.79 | HTR2A (0.55) | HTR2AHTR2CHTR2B | |
| SCHEMBL3285489 | 0.79 | HTR2A (0.55) | HTR2AHTR2CHTR2B | |
| SCHEMBL3290141 | 0.79 | HTR2A (0.55) | HTR2AHTR2CHTR2B | |
| SCHEMBL23745298 | 0.76 | ESR1 (0.48) | HTR2AHTR2CHTR2BNOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100331312-A1 | MODULATORS OF THE HISTAMINE H3 RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| EP-2265587-A1 | MODULATORS OF THE HISTAMINE H3 RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2010-12-29 | — | — | EP | disclosed |
| WO-2009105206-A1 | MODULATORS OF THE HISTAMINE H3 RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2009-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331312-A1 | MODULATORS OF THE HISTAMINE H3 RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | HRH3, HRH4, HRH1 | HTR2A 18/4885HTR2C 37/4885HTR2B 51/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.